Leerink upgraded Ionis Pharmaceuticals to Outperform from Market Perform with a price target of $62, up from $53. As the company transitions to its wholly-owned assets, investor focus has shifted toward olezarsen and donidalorsen as a series of assets reach commercialization, the analyst tells investors in a research note. The firm sees upward pressure on estimates as Angelman syndrome value flows into models. Leerink upgraded the shares following the Angelman syndrome update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharma’s ION582 shows positive Phase 1/2 results in Angelman syndrome
- Ionis Pharmaceuticals completes enrollment in trial of zilganers in AxD
- Ionis Pharmaceuticals price target raised to $67 from $64 at BofA
- Ionis Pharmaceuticals assumed at Buy from Underperform at Jefferies
- Ionis Pharmaceuticals price target raised to $53 from $50 at Stifel